|
WO2021028337A1
|
|
Peptide antigens and uses thereof
|
|
WO2021028338A1
|
|
Method of identifying peptide antigens and uses thereof
|
|
WO2021013884A1
|
|
Inhibitors of chi3l1 and their uses
|
|
EP3705893A1
|
|
Methods to assess the risk of being affected by prostate cancer
|
|
EP3669885A1
|
|
Use of sap for the treatment of eurotiomycetes fungi infections
|
|
WO2019081591A1
|
|
Nk or t cells and uses thereof
|
|
WO2019057780A1
|
|
Anti-human migration stimulating factor (msf) and uses thereof
|
|
EP3192805A1
|
|
Inhibitors of t cell activation or stimulation and uses thereof
|
|
EP3165926A1
|
|
Method for characterization of cell specific microvesicles
|
|
EP3121289A1
|
|
Micrornas as biomarkers of bile duct diseases
|
|
EP2883962A1
|
|
High levels of EMT-TFs for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer
|
|
WO2011104671A1
|
|
Novel water soluble furoxan derivatives having antitumor activity
|
|
EP2376461A1
|
|
Nitric oxide furoxan derivative compounds endowed with antitumoral activity
|
|
WO2010081488A1
|
|
Nitric oxide furoxan derivative compounds endowed with antitumoral activity
|
|
WO2010040362A1
|
|
Antibodies against rns-induced modified cytokines and uses thereof
|
|
WO2010010582A1
|
|
Antibiogram method and kit
|
|
WO2009013770A1
|
|
Derivatised polysaccharide material for the transdermal administration of drugs
|
|
AU2006352299A1
|
|
A method for measuring plasma levels of long pentraxin PTX3
|
|
CA2632952A1
|
|
Diagnostic test for inflammatory endothelial dysfunctions in pregnancies
|
|
CA2652658A1
|
|
"in vitro" diagnostic method for diseases affecting human or animal tissues
|
